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Interplay between spinal cord and cerebral
cortex metabolism in amyotrophic
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We recently reported the potential of Hough transform in delineating spinal cord metabolism by 18F-fluorodeoxyglucose PET/CT
scanning in amyotrophic lateral sclerosis. The present study aimed to verify the relationship between spinal cord and brain
metabolism in 44 prospectively recruited patients affected by amyotrophic lateral sclerosis submitted to 18F-fluorodeoxyglucose
brain and whole-body PET/CT. Patients were studied to highlight the presence of brain hypo- or hypermetabolism with respect to
healthy controls, and multiple regression analysis was performed to evaluate the correlation between spinal cord and brain
metabolism. Our results confirmed higher 18F-fluorodeoxyglucose uptake in both cervical and dorsal spinal cord in patients
with amyotrophic lateral sclerosis with respect to controls. This finding was paralleled by the opposite pattern in the brain
cortex that showed a generalized reduction in tracer uptake. This hypometabolism was particularly evident in wide regions of
the frontal-dorsolateral cortex while it did not involve the midbrain. Bulbar and spinal disease onset was associated with similar
degree of metabolic activation in the spinal cord. However, among spinal onset patients, upper limb presentation was associated
with a more pronounced metabolic activation of cervical segment. Obtained data suggest a differential neuro-pathological state or
temporal sequence in disease progression.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disorder, characterized by a degeneration of upper and
lower motor neurons leading to a progressive muscular
paralysis. Although median survival most often averages
3–4 years, the large variability of its course (Calvo et al.,
2017) raises an urgent need to develop biomarkers able to
characterize the mechanisms underlying disease progression
and to improve the diagnostic yield of clinical and neuro-
physiological evaluation.
Most studies in this setting focused on cortical response
to ALS. Among these approaches, brain PET studies with
18F-fluorodeoxyglucose (FDG) already reported a signifi-
cant reduction in glucose metabolism (Pagani et al., 2014)
in motor and premotor cortex (Kiernan et al., 1994;
Abrahams et al., 1996, 2005). By contrast, involvement
of the spinal cord has been characterized in relatively
lower detail, mostly because of the anatomical features of
this structure that limit the standardization of its evalu-
ation. Consequently, a large uncertainty still exists about
the mechanisms underlying ALS-induced damage in the
spinal cord and its relationship with cortical impairment.
We recently reported the potential of the Hough transform
in delineating spinal cord structure and metabolic activity
in a population of ALS patients subjected to FDG PET/CT
(Marini et al., 2016). Specifically, this classical pattern rec-
ognition approach for the automatic identification of
straight lines in the image has been recently extended to
the recognition of more complex shapes. This computa-
tional 3D approach enabled the extraction of spinal cord
metabolic information from whole body images and per-
mitted us to document increased glucose consumption, pos-
sibly representing a potential and independent prognostic
marker (Marini et al., 2016).
In the present study, we simultaneously analysed brain
and spinal cord FDG uptake in a series of prospectively
recruited patients submitted to brain and whole-body
PET/CT.
Materials and methods
Patients with amyotrophic lateral
sclerosis
The study included 44 prospectively recruited patients with
definite, probable or probable laboratory-supported ALS diag-
nosis according to the revised El-Escorial criteria (Brooks
et al., 2000). None of them had any history of other
neurological disorders, cerebrovascular disease, diabetes melli-
tus or systemic inflammatory disease. All subjects provided
signed informed consent to enter the study that was approved
by the Ethics Committees of IRCCS Ospedale Policlinico San
Martino in Genoa, and of AUO Citta` della Salute e della
Scienza in Turin, Italy.
Control subjects
Brain PET from patients with ALS were compared with the
corresponding data of 44 healthy volunteers who gave their
informed consent. As described by Morbelli et al. (2017), their
healthy condition was carefully checked by means of clinical
and neuropsychological examination, brain MRI and by the
same exclusion criteria as used for ALS patients. A case–con-
trol criterion was adopted to reproduce the same age range,
gender distribution and educational level of ALS patients.
For ethical considerations, PET/CT scan was not extended to
the body of these normal volunteers. Accordingly, PET spinal
cord data were compared with the corresponding findings of
44 control subjects without any history of neurodegenerative
disease, randomly selected from a previously published nor-
malcy database (Sambuceti et al., 2012), again according to
a case–control criterion.
PET/CT imaging
All PET/CT scans were acquired according to current guide-
lines (Varrone et al., 2009) as detailed in the Supplementary
material.
Spinal cord analysis
The entire CT dataset was co-registered with the 3D PET
images using commercially available software interfaces.
Image analysis was performed by means of a pattern recogni-
tion algorithm based on an extension of the Hough transform
to algebraic curve. As described in the Supplementary material,
this approach uses an operator-independent fully deterministic
algorithm to identify the spinal canal and to extract spinal
cord FDG uptake expressed as standardized uptake value
(SUV) according to the method previously validated in our
laboratory, which is described elsewhere (Sambuceti et al.,
2012; Beltrametti et al., 2013; Massone et al., 2015).
The cervical spinal cord segment was defined as the region
between skull basis and the plane adjacent to the caudal face
of C7 vertebral body. Dorsal segment was defined as the dis-
trict included between this plane and the one adjacent to the
caudal face of D12. Lumbar and sacral canal districts were a
priori excluded.
Brain PET analysis
Statistical Parametric Mapping (SPM) analysis was performed
as previously described (Morbelli et al., 2017) and detailed in
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the Supplementary material. To compare ALS effects on global
consumption of brain and spinal cord, SPM analysis of FDG
uptake distribution was complemented with the evaluation
of absolute tracer retention. Accordingly, the preprocessed
NifTI-1 PET images were converted in whole-brain SUV
parametric maps dividing the product between radiotracer
concentration (kBq/ml) and body weight (in kg) by the injected
FDG dose (in MBq) (Cistaro et al., 2012; Ku¨ntzelmann et al.,
2013; Annen et al., 2016). Thereafter, WFU PickAtlas and
NiftyReg were used to automatically identify volumes of
interest corresponding to 41 Brodmann areas (BAs) in both
hemispheres. All data are reported as mean  standard devi-
ation (SD). Unpaired or paired t-tests were used, as appropri-
ate. P-values5 0.05 were considered significant. Analyses were
performed using SPSS package (version 21).
Results
Clinical characteristics of patient
population
As reported in Supplementary Table 1, age, sex, and ideal
body weight were similar in control and ALS subjects. ALS
Functional Rating Scale Revised (ALSFRS-R) score, updated
at imaging date, was 39  4 (range 28–45). Mean time
elapsed from clinical disease onset and PET/CT scanning
was 20  15 months (range 8–81 months, median 14
months) while mean interval between ALS diagnosis and
imaging was 10  9 months.
Spinal cord metabolism
FDG uptake was significantly higher in the whole spinal
cord of ALS patients with respect to controls (0.81  0.4
versus 0.67  0.2, P = 0.05). This difference was more pro-
nounced in cervical segments (1.08  0.2 versus
0.82  0.2, P5 0.01) and relatively less evident in dorsal
metameres (0.69  0.2 versus 0.57  0.2, P50.05). Effect
of ALS on spinal cord metabolism was independent from
demographic and clinical variables as well as from time
elapsed from diagnosis to imaging. Likewise, spinal cord
metabolic activation was similar in spinal or bulbar onset
ALS. Yet, the regional agreement between increased FDG
uptake and clinical motor impairment could be docu-
mented in the 33/35 spinal patients in whom predomin-
antly upper (n = 12) or lower (n = 21) limb involvement
was well defined at diagnosis (Fig. 1). Upper limb onset
was associated with a more pronounced metabolic activa-
tion in the cervical segment (Fig. 1). The selectivity of this
metabolic response was confirmed by the ratio between
cervical and dorso-lumbar spinal cord tracer retention
that was significantly higher in patients with upper limb
Figure 1 Spinal cord metabolism in upper and lower limb clinical onset. (A and C) 3D reconstructions of spinal cord FDG uptake, in a
patient with upper or lower ALS onset, respectively. (B) The corresponding SUV values plotted from cervical slices (top) to lumbar ones (bottom).
Tracer retention is higher in cervical segments in upper limb presentation, while the reverse gradient occurs in lower limb onset. (D) Average SUV
values in the two spinal cord districts: in patients with upper limb onset tracer uptake in the cervical spinal cord is higher with respect to both the
dorsal segment in the same patients and with respect to the same segment in the remaining subjects. This selective localization is confirmed by the
ratio cervical/dorso-lumbar tracer uptake reported in E. ns = not significant; SC = spinal cord.
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clinical onset (Fig. 1). By contrast, the difference in FDG
uptake of caudal spinal cord did not reach the statistical
significance in patients with lower limb involvement (Fig. 1).
SPM analysis of amyotrophic lateral
sclerosis effect on brain FDG
distribution
SPM-based group analysis highlighted a wide hypometa-
bolic cluster involving frontal dorso-lateral cortex bilat-
erally as well as the precentral and temporal cortex in the
left hemisphere (Fig. 2A and Table 1). Conversely, hyper-
metabolic cluster was markedly smaller and mainly
involved the midbrain (Fig. 2B and Table 1). This meta-
bolic pattern was reproduced in spinal as well as in bulbar
onset patients. Bulbar onset was instead associated with a
more severe metabolic impairment in bilateral precentral
gyri (BA 6) and in left putamen (Supplementary Fig. 1).
Among the 35 patients with spinal ALS, right onset was
associated with a more severe metabolic impairment in the
left premotor cortex (BA 6) and in the left temporal cortex
(BA 39) as well as in the right postcentral gyrus (BA 3)
(Supplementary Fig. 2). By contrast, no appreciable differ-
ence in brain metabolism was identified between ALS pa-
tients classified according to upper or lower limb clinical
onset (data not shown).
Mean SUV of cervical spinal cord was significantly and
inversely correlated with hypometabolism in the pre- and
para-central gyri bilaterally but particularly in the left
hemisphere (Fig. 2C and Table 1). Similarly, dorsal spinal
cord mean SUV predicted a relative hypometabolism in the
temporo-lateral and frontal dorso-lateral cortex in the left
hemisphere (Fig. 2D and Table 1). Finally, neither cervical
nor dorsal spinal cord metabolism were significantly corre-
lated with midbrain metabolic pattern.
Volumes of interest analysis
FDG uptake, estimated by average SUV of automatically
identified volumes of interest, was significantly lower in
ALS patients with respect to controls in virtually all analysed
BAs (Fig. 3). As a consequence, this same observation also
applied when the average SUV of the whole cortical volume
was considered (4.93  1.40 versus 5.95  1.65, respect-
ively, P50.01). Similarly, ALS was associated with lower
SUV in thalamus (5.31  1.76 versus 6.4  1.7, respectively,
P5 0.01), basal ganglia (6.17  1.75 versus 7.2  2.0, re-
spectively, P5 0.01) and cerebellum (3.1  1.98 versus
5.6  1.5, respectively, P5 0.01).
Discussion
The main finding of the present study is the divergent
metabolic response to ALS in brain and spinal cord.
Brain displays a generalized reduction in glucose con-
sumption particularly evident in motor and premotor
cortex. By contrast, spinal cord displays a moderate in-
crease in FDG uptake that can be more easily detected in
its cervical segment. The interplay between the two oppos-
ite metabolic patterns, documented by this transversal and
simultaneous picture, indicates a divergent nature or a di-
vergent time-course of the mechanisms underlying ALS-
related damage to upper and lower motor neurons.
In agreement with our previous observation (Marini et al.,
2016), the analysis of spinal cord metabolic pattern showed
a significant increase in FDG uptake in the spinal cord of
ALS patients. The reproducibility of this finding and its oc-
currence in a cohort of prospectively and independently re-
cruited ALS subjects confirm that ‘metabolic spinal cord
activation’ might occur in a high number of ALS patients
and might thus track pathophysiological mechanisms poten-
tially contributing to disease progression. This concept is
corroborated by the observation that, among spinal onset
ALS patients, upper limb presentation was associated with
a more pronounced metabolic activation of cervical spinal
cord. This finding thus suggests that spinal cord metabolic
activation might track some process related to motor impair-
ment on a regional basis. Actually, the opposite pattern was
not observed in patients with lower limb involvement most
likely because of the limited spatial resolution hampering the
evaluation of caudal spinal cord because of contaminations
related to both partial volume effect and uncertainty in the
definition of caudal spinal cord border.
On the other hand, SPM analysis of brain FDG distribu-
tion confirmed previous studies in larger numbers of pa-
tients reporting small areas of relative hypermetabolism
virtually limited to the midbrain and large hypometabolic
clusters in the frontal dorso-lateral cortex (Cistaro et al.,
2012; Pagani et al., 2014) with the uncus involved only in
our series. Accordingly, the simultaneous coupling of both
evaluations provided a new and, under many points of
view, unexpected glance at available data about ALS meta-
bolic effect on the CNS.
Currently, SPM is one of the most widely used standards
to evaluate brain FDG images. In conventional ‘static’ PET
studies, this procedure analyses the original reconstructed
data reporting radioactivity concentration (in kBq/ml) in
each voxel. These source images are thus scaled to an intra-
cranial reference region to identify areas of relative acti-
vation (hypermetabolism) or stilling (hypometabolism).
However, scaling procedure intrinsically prevents the cap-
ability to identify generalized reductions in brain glucose
consumption. Indeed, several authors argued about the in-
terpretation of voxelwise-highlighted hypermetabolic clus-
ters that might reflect a true metabolic activation as well
a relatively less severe metabolic deceleration in neurode-
generative disorders (Ku¨ntzelmann et al., 2013).
To overcome this limitation, and to replicate the analysis
criteria adopted for spinal cord evaluation, we processed
the original data of tracer concentration to calculate aver-
age SUV in each automatically detected volume of interest.
Obviously, this procedure does not account for both FDG
persistence in the circulating blood and competition by
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serum glucose level. Nevertheless, its capability to abolish
the interference of the main methodological determinants of
tracer uptake—administered dose and body weight—per-
mitted us to detect a generalized reduction of FDG
uptake in studied ALS patients.
This finding confirms previous dynamic PET studies that
reported a generalized and progressive reduction of glucose
consumption in ALS brain partially related to disease dur-
ation (Dalakas et al., 1987), degree of cognitive decline
(Ludolph et al., 1992) or severity of upper motor neuron
involvement (Hoffman et al., 1992). Similarly, localization
of metabolic impairment, provided by voxelwise analysis,
closely agrees with the thinning of the primary motor
cortex previously documented by MRI in ALS patients
(Verstraete et al., 2010) and also with recent (Eisen et al.,
2017) and older neuropathological studies reporting abnorm-
alities not only in the Betz area (Lawyer et al., 1953) but also
in the adjacent gyri and in the deeper parts of the brain
(Smith et al., 1960). Unfortunately, the lack of coregistered
PET and MRI images prevents the possibility to define
whether the reduced tracer uptake in hypometabolic areas
reflects a reduced density of cells with an intact metabolism,
a reduced metabolic rate of glucose consumption by normal
populations of synapses or both mechanisms. Nevertheless,
the same analytical approach documented that the metabolic
activation of spinal cord faced a global impairment in glu-
cose consumption involving the vast majority of encephalic
structures.
The mechanisms underlying this opposite response
cannot be identified by the present data. Nevertheless,
post-mortem studies document the activation of microglia
(Beers et al., 2006), oligodendrocytes (Lee et al., 2012) and
astrocytes (Nagai et al., 2007) in tissues harvested from
motor cortex and spinal cord of both ALS patients and
Figure 2 SPM analysis. 3D rendering showing regions in which FDG uptake was significantly lower (A) or higher (B) in ALS patients with
respect to controls. (C and D) Results of the multiple regression analysis between brain and cervical or dorsal spinal cord metabolism,
respectively. Threshold P5 0.05, corrected for multiple comparisons with the FDR at the voxel level were set in each analysis. Coordinate and
regional details are presented in Table 1.
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experimental models of ALS. In particular, astrocytic acti-
vation nicely fits with the notion that these cells account for
most of the FDG accumulation in the brain (Zimmer et al.,
2017). Defining these mechanisms is obviously far beyond
the scope of this clinical and observational study.
Nevertheless, the divergent pattern of FDG uptake in the
spinal cord and brain indicates that the metabolic response
of these two districts follows different pathways or different
time sequences. Accordingly, monitoring the temporal evo-
lution of damage in the first and in the second motor
neuron might represent an important clue to improve our
understanding of ALS pathophysiology.
Obviously, a direct estimation of brain glucose consump-
tion would have provided a more detailed description of
metabolic pattern in both brain and spinal cord (Hustinx
et al., 1999). Ethical concerns prevented the possibility to
perform a complex series of acquisitions with dynamic se-
quence followed by brain and whole-body scans.
Nevertheless, the decreased FDG uptake in the brain, to-
gether with the opposite response of spinal cord SUV,
strongly support the concept that hypermetabolic brain
clusters identified by SPM analysis probably reflect areas of
relatively preserved glucose consumption rather than the con-
sequence of neuronal activation (Pagani et al., 2014).
As a main limitation of our study, brain and spinal cord
metabolic patterns of ALS patients were compared with
normalcy databases harvested from different populations.
In brain-image donors, this limitation was justified by the
ethical concern in extending CT scan to the whole body of
normal volunteers. For normal spinal cord evaluation, the
ethical concern was related to the need to avoid modifica-
tions to the standard protocol of oncologic imaging that
does not include the pre-scan procedure needed for cerebral
PET/CT. As a further limitation, the limited patient sample
and the relatively wide inclusion criteria did not permit us
to verify any possible correlation between degree/site of
spinal cord metabolic activation and force generated by
the related muscular districts. A similar consideration
applies to the side coherence between brain metabolism
and motor involvement. Actually, when compared with
left onset, right onset ALS was associated with a more
severe metabolic impairment in the left hemisphere.
Table 1 SPM analysis














Cortical regions of relative hypometabolism
1357 0.0001 L-limbic 5.48 33 9 34 Uncus 20
L-limbic 5.35 36 18 26 Uncus 20
L-temporal 4.78 45 22 21 Fusiform gyrus 20
1619 0.0001 L-frontal 5.06 49 1 45 Middle frontal gyrus 6
L-frontal 4.97 32 15 51 Superior frontal gyrus 8
R-frontal 4.58 15 30 49 Superior frontal gyrus 8
Cortical regions of relative hypermetabolism
384 0.01 R-frontal 5.19 11 19 13 Superior frontal gyrus 8
R-sublobar 4.74 23 8 8 Amygdala
R-sublobar 3.83 13 2 0 Lentiform nucleus
R-sublobar 3.50 36 9 16 Insula 13
379 0.01 R-midbrain 4.69 7 18 19
Correlation between cervical spinal cord and brain metabolism
349 0.01 L-frontal 4.13 5 40 57 Paracentral lobule 5
R-frontal 4.11 15 24 69 Precentral gyrus 4
L-frontal 3.62 5 30 56 Paracentral lobule 6
Correlation between dorsal spinal cord and brain metabolism
409 0.01 R-sublobar 4.75 42 7 16 Insula 13
R-sublobar 3.55 41 4 12 Insula 13
R-sublobar 3.39 34 14 15 Claustrum
347 0.01 L-frontal 4.46 13 23 49 Superior frontal gyrus 6
L-limbic 3.79 7 17 37 Cingulate gyrus 32
L-limbic 3.48 5 0 42 Cingulate gyrus 24
590 0.01 L-sublobar 4.07 34 9 15 Insula 13
L-sublobar 3.49 36 2 23 Insula 13
L-frontal 3.30 41 6 36 Precentral gyrus 9
436 0.01 L-frontal 3.55 49 35 18 Middle frontal gyrus
L-frontal 3.16 25 34 21 Medial frontal gyrus 9
L-frontal 3.14 31 30 32 Middle frontal gyrus 9
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However, this finding must be interpreted cautiously be-
cause of the possible occurrence of several biases related
to the limited sample size and the variable side with most
prominent symptoms at time of scan.
In conclusion, the present transversal and observational
study documents a divergent metabolic response to ALS by
spinal cord and brain. This evidence indicates that what-
ever mechanism affects glucose consumption of the CNS in
ALS, its nature or its time course profoundly differ in upper
and lower motor neurons. This divergent behaviour indi-
cates that complementing brain imaging with the extraction
of spinal cord information might improve the informative
potential of PET studies with tracers selectively interrogat-
ing specific pathophysiological mechanisms underlying ALS
progression.
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